Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Chronic infection with Pseudomonas aeruginosa is a major cause of the lung damage seen in people with cystic fibrosis (CF). Sildenafil (RevatioÂ®), a drug already used in other types of lung disease, may be helpful in decreasing symptoms related to lung inflammation and infection in people with CF. Study participants will receive sildenafil or placebo. Specimens of blood and sputum will be taken along with pulmonary function testing. The study will last 14 weeks.
>= 12 Years
>= 40 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
National Jewish Health (Adult), Denver, CO, 80206
Jones, Marion Phone: (303) 398-1265 Email: firstname.lastname@example.org
University of New Mexico School of Medicine (Adult), Albuquerque, NM, 87131
Redway, Abby Phone: (505) 272-5886 Email: email@example.com